TY - JOUR
T1 - A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine
AU - Sawada, Masanori
AU - Sugiyama, Daisuke
AU - Nii, Takenobu
AU - Konno, Katsuhiro
AU - Kagimoto, Hardy T.S.
N1 - Funding Information:
This work was supported in part by Japan Agency for Medical Research and Development ( AMED ) under grants JP17lm0203009j and JP15lk0503007j .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/11
Y1 - 2018/11
N2 - Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.
AB - Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.
UR - http://www.scopus.com/inward/record.url?scp=85055911658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055911658&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2018.10.001
DO - 10.1016/j.clinthera.2018.10.001
M3 - Article
C2 - 30396514
AN - SCOPUS:85055911658
SN - 0149-2918
VL - 40
SP - 1801
EP - 1806
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 11
ER -